MedTrace Logo

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

NCT00030472 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-04-11

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have persistent or recurrent cancer of the cervix.

Conditions

Interventions

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Peter G. Rose, MD · MetroHealth Cancer Care Center at MetroHealth Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Primary Completion
2006-10-31

Countries

  • United States
  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030472 on ClinicalTrials.gov